Protocol Ledger

NCT04918173 · Phase III · RECRUITING

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Interventional Phase III clinical trial protocol NCT04918173 sponsored by Octapharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-07-01 Enrollment: 38 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04918173
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)38 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04918173
Protocol FieldVerified Registry Value
NCT IdentifierNCT04918173
Consolidated Lead SponsorOctapharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment38 participants (ESTIMATED)
Registered Start Date2022-07-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI